Investigational drug · Phase 3
Pucotenlimab
Also called: HX008
Not approved by FDA. In 6 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Head and Neck Squamous Cell Carcinoma, Melanoma, Hepatocellular Carcinoma.
Phase 3Last checked: Nov 19, 2026Latest source record: Sep 4, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
6
6 still active
All registered trials
61
Any phase or sponsor naming "Pucotenlimab"
First trial start
2020
Dec 1, 2020
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "Pucotenlimab", any sponsor or status.
- Phase 254
Conditions studied
As listed on its trial records.
- Head and Neck Squamous Cell Carcinoma
- Melanoma
- Hepatocellular Carcinoma
- Recurrent or Metastatic Nasopharyngeal Carcinoma
- Advanced Solid Tumors
- Metastatic Colorectal Cancer
Approved drugs for the same conditions: Colorectal cancer · Melanoma · Liver cancer (hepatocellular carcinoma) · Head and neck cancer · Oncology
Largest trials
Live from ClinicalTrials.gov: studies naming "Pucotenlimab" as an intervention, largest first.
- Neoadjuvant CAPOX With or Without Pucotenlimab Plus Selective Radiotherapy for Locally Advanced Rectal CancerPivotal-lookingRecruiting
Sun Yat-sen UniversityAcademic, hospital or other
NCT07528209 · 556 participants (planned) · Start Apr 20, 2026 · Primary completion Apr 20, 2032
Drug: Pucotenlimab combine with CAPOX; CAPOX · For: Rectal Cancer; pMMR (Microsatellite Stable Rectal Cancer)
Sites: Guangzhou, China
- A Study of MRG003 in Combination With Pucotenlimab Versus Chemotherapy in the Treatment of Patients With Recurrent or Metastatic Nasopharyngeal CarcinomaPivotal-lookingRecruiting
Lepu Biopharma Co., Ltd.Industry
NCT06976190 · 446 participants (planned) · Start May 6, 2025 · Primary completion May 2029
Drug: MRG003 + Pucotenlimab; Gemcitabine, Docetaxel, or Capecitabine · For: Recurrent or Metastatic Nasopharyngeal Carcinoma
Sites: Guangzhou, China
- Becotatug Vedotin (MRG003) in Combination With PD-1 Inhibitor Versus PD-1 Inhibitor for the Treatment of EGFR-positive, CPS≥1 Resectable Locally Advanced Head and Neck Squamous Cell CarcinomaPivotal-lookingRecruiting
Ming-Yuan ChenAcademic, hospital or other
NCT07524452 · 430 participants (planned) · Start Feb 6, 2026 · Primary completion Feb 28, 2031
Drug: Neoadjuvant and Adjuvant Becotatug Vedotin; Neoadjuvant and Adjuvant Immunotherapy and 1 more · For: Locally Advanced Head and Neck Squamous Cell Carcinoma
Sites: Zhuhai, China
- Dynamic Plasma EBV DNA-Guided Risk-Adapted Treatment With Becotatug Vedotin (MRG003) Plus PD-1 Blockade in Locoregionally Advanced Nasopharyngeal CarcinomaNot yet recruiting
Sun Yat-sen UniversityAcademic, hospital or other
NCT07524413 · 298 participants (planned) · Start Dec 2026 · Primary completion Dec 2031
Drug: Becotatug Vedotin; Pucotenlimab and 2 more · For: Nasopharyngeal Cancinoma (NPC); Nasopharyngeal Cancer
- A Study of HX008 Compared to Chemotherapy in the First-Line Treatment of Subjects With MSI-H/dMMR Metastatic Colorectal CancerPivotal-lookingActive, not recruiting
Taizhou Hanzhong biomedical co. LTDIndustry
NCT05652894 · 190 participants (planned) · Start Feb 28, 2023 · Primary completion Jun 30, 2026
Drug: HX008(Pucotenlimab); Investigator's Choice Chemotherapy · For: Metastatic Colorectal Cancer
Sites: Bengbu, China; Fuyang, China; Hefei, China · 63 sites in all
- Study of Becotatug Vedotin Added to Standard Treatment for Advanced Bile Duct Cancer With EGFR MutationsPivotal-lookingNot yet recruiting
Sir Run Run Shaw HospitalAcademic, hospital or other
NCT07598318 · 164 participants (planned) · Start May 20, 2026 · Primary completion Dec 31, 2027
Drug: Becotatug Vedotin; Pucotenlimab and 2 more · For: Cholangiocarcinoma
Lepu Biopharma Co., Ltd.Industry
NCT07479485 · 160 participants (planned) · Start Apr 8, 2026 · Primary completion Apr 2028
Drug: MRG006A; Pucotenlimab and 3 more · For: Hepatocellular Carcinoma
Sites: Beijing, China; Fuzhou, China; Zhengzhou, China · 8 sites in all
- Clinical Trial Comparing Induction Treatment With EGFR-ADC MRG003 Alone or in Combination With the Anti PD1 Pucotenlimab, Followed by Radiochemotherapy in Locally Advanced Squamous Cell Cancers of the Head and NeckPivotal-lookingRecruiting
Groupe Oncologie Radiotherapie Tete et CouAcademic, hospital or other
NCT06959108 · 106 participants (planned) · Start Oct 13, 2025 · Primary completion Jun 2029
Drug: Pucotenlimab; MRG003 · For: Locally Advanced Head and Neck Squamous Cell Carcinoma
Sites: Villejuif, France
- Becotatug Vedotin Combined With Pucotenlimab for Locally Recurrent Resectable Head and Neck Squamous Cell CarcinomaPivotal-lookingRecruiting
Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong UniversityAcademic, hospital or other
NCT07632339 · 102 participants (planned) · Start Jun 16, 2026 · Primary completion Jun 16, 2028
Drug: Becotatug Vedotin combined with Pucotenlimab · For: Head and Neck Cancer
Sites: Shanghai, China
- Clinical Efficacy of Pucotenlimab Combined With Lenvatinib and SOX Versus SOX Alone in Patients With HER2-Negative Advanced Gastric or Gastroesophageal Junction AdenocarcinomaPivotal-lookingEnrolling by invitation
Fujian Medical UniversityAcademic, hospital or other
NCT07356466 · 100 participants (planned) · Start May 1, 2025 · Primary completion Apr 30, 2027
Drug: Pucotenlimab Combined with Lenvatinib; Oxaliplatin plus S-1 regimen · For: Gastric (Stomach) Cancer
Sites: Fuzhou, China
Newest research
PubMed records naming it or its code names, newest first.
- Becotatug Vedotin Combined With Pucotenlimab in Platinum- and Immunotherapy-Resistant Recurrent or Metastatic Nasopharyngeal Carcinoma.
Ruan DY, Wang FH, Zhou Y, et al. · J Clin Oncol 2026
- MH-Penile-002: a phase II, prospective, single-arm trial of neoadjuvant anti-EGFR antibody-drug conjugate plus PD-1 inhibitor in penile cancer with challenging penile preservation or regional lymph node metastasis.
Wang JY, Shao YX, Yang LL, et al. · Future Oncol 2026
- Fulminant toxic epidermal necrolysis induced by pucotenlimab in a patient with lung adenocarcinoma: a case report.
Zhang Z, Tao Q, Wang J, et al. · Front Oncol 2026
- Integration Analysis of Bayesian and Machine Learning for Heterogeneity, Biomarkers, and Optimal Combination Regimens of Pucotenlimab in Solid Tumors.
He Y, Gao C, Zhang S, et al. · Cancer Med 2026
- Severe neuromyelitis optica spectrum disorder induced by pucotenlimab: a case report and literature review.
Zhang Z, Liao L, Zhou H, et al. · Front Immunol 2026
- Adjuvant short-course radiotherapy combined with chemotherapy and a PD-1 inhibitor for resected mucosal melanoma: study protocol for a single-arm, prospective, phase II trial.
Lv J, Shen L, Jiang X, et al. · BMJ Open 2026
Also in development for Head and Neck Squamous Cell Carcinoma
- BMS-986507BL-B01D1, Iza-brenPhase 351 trials
Sichuan Baili Pharmaceutical Co., Ltd. · Non-small Cell Lung Cancer, Solid Tumor, Urothelial Carcinoma
- HS-20093Ris-Rez, Risvutatug rezetecanPhase 316 trials
Hansoh BioMedical R&D Company · Neoplasms, Lung, Sarcoma, Osteosarcoma
- Telisotuzumab AdizutecanABBV-400Phase 316 trials
AbbVie · c-MET, Non-Squamous Non-Small Cell Lung Cancer, Metastatic Colorectal Cancer
- SG001enlonstobart, Enlonstobart will be administrated on a 14-day cyclePhase 315 trials
CSPC Megalith Biopharmaceutical Co.,Ltd. · HER2-positive Gastric Cancer, Esophageal Squamous Cell Carcinoma, Head and Neck Squamous Cell Carcinoma
- SYS6010Phase 315 trials
CSPC Megalith Biopharmaceutical Co.,Ltd. · Non-Small Cell Lung Cancer, Esophageal Squamous Cell Carcinoma, Head and Neck Squamous Cell Carcinoma
- AK117Phase 314 trials
Akeso · Advanced Malignant Tumors, ACUTE MYELOID LEUKEMIA; AML, Higher-risk Myelodysplastic Syndromes
- FianlimabREGN3767Phase 311 trials
Regeneron · Melanoma, Non-small Cell Lung Cancer, Hepatocellular Carcinoma
- ZanzalintinibXL092Phase 311 trials
Exelixis · Colorectal Cancer, Renal Cell Carcinoma, Head and Neck Squamous Cell Carcinoma
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.